Streetbeat News

PLSE

Pulse Biosciences, Inc.

https://www.pulsebiosciences.com

Industry

Medical - Instruments & Supplies

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Open

16.27

Mkt cap

1.1B

Volume

138K

High

17.71

P/E Ratio

-21.30

52-wk high

22.69

Low

16.05

Div yield

N/A

52-wk low

6.59

SentinelOne shares dropped 16% after reporting mixed Q1 results, with a significant earnings miss but a slight revenue beat. Other notable stock movements include gains for Novo Integrated Sciences, Latam Logistic Properties, and Digital Health Acquisition Corp, and losses for Smart for Life, Sify Technologies, and MongoDB.

Portfolio Pulse from Avi Kapoor

May 31, 2024 | 5:17 pm

The article highlights significant intraday movements in health care stocks on Friday. Notable gainers include Novo Integrated Sciences (NVOS), Anebulo Pharmaceuticals (ANEB), Annovis Bio (ANVS), Vaccinex (VCNX), Genprex (GNPX), and Purple Biotech (PPBT). Significant losers include Calidi Biotherapeutics (CLDI), Summit Therapeutics (SMMT), Heart Test Laboratories (HSCS), Humacyte (HUMA), Concord Medical Services (CCM), and Pulse Biosciences (PLSE).

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 4:31 pm

The article highlights the pre-market movements of various health care stocks on Friday. Notable gainers include Novo Integrated Sciences (NVOS), Adaptimmune Therapeutics (ADAP), and Bionomics (BNOX). Significant losers include Summit Therapeutics (SMMT), Genfit (GNFT), and Veeva Systems (VEEV).

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 12:06 pm

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation Technology will be featured in several presentations at the HRS 2024 Annual Meeting, highlighting its potential in treating atrial fibrillation.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 12:16 pm

Bolt Biotherapeutics shares fell 34% after reporting a GAAP loss of 28 cents per share on $5.30 million in sales. Analysts from Guggenheim and Stifel downgraded the stock. Other stocks like AERWINS Technologies and Sintx Technologies saw significant gains, while Virpax Pharmaceuticals and Yield10 Bioscience experienced notable losses.

Portfolio Pulse from Avi Kapoor

May 15, 2024 | 5:38 pm

Pulse Biosciences, Inc. (NASDAQ:PLSE) announces leadership changes to support growth, appointing Burke T. Barrett as CEO and Kevin Danahy as Chief Commercial Officer. These changes come as the company prepares for the pilot launch of its FDA-cleared CellFX nsPFA Percutaneous Electrode System.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:31 pm

Nuvve Holding Corp. shares plummeted by approximately 30% after reporting Q4 financial results significantly below market expectations. Other stocks experienced notable movements, with Vast Renewables and CXApp Inc. leading the gainers, while Eiger BioPharmaceuticals and Andretti Acquisition Corp. were among the biggest losers.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 6:31 pm

Pulse Biosciences' stock is trading lower following the announcement of its Q4 financial results and plans to initiate a rights offering of up to $60 million worth of units.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 5:24 pm

U.S. stock futures are trading higher, with focus on PVH Corp., Oxford Industries, Natural Gas Services Group, Torrid Holdings, and Pulse Biosciences due to earnings reports and financial results. PVH is expected to report earnings of $3.52 per share, Oxford Industries reported disappointing results and weak guidance, Natural Gas Services is anticipated to earn 6 cents per share, Torrid Holdings reported strong Q4 results, and Pulse Biosciences announced a loss and a rights offering.

Portfolio Pulse from Avi Kapoor

April 01, 2024 | 7:33 am

In Friday's after-market session, several healthcare stocks showed significant movement. Notably, Qilian Intl Hldg Gr, Sunshine Biopharma, and Galera Therapeutics were among the top gainers, with Qilian Intl leading with a 63.8% increase. On the downside, Vivos Therapeutics, ENDRA Life Sciences, and Applied Therapeutics experienced notable declines, with Vivos Therapeutics dropping 22.4%. The movements were largely attributed to the release of Q4 earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

March 29, 2024 | 8:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.